Somatic mutations in TP53 are known to occur early in breast cancer35 and Ductal Carcinoma In-Situ (DCIS), preceding invasion, and the mutation frequency increases with the grade of DCIS tumors. Here, TP53 is linked to ductal breast carcinoma in situ.